Literature DB >> 25140861

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Eva Tiensuu Janson1, Halfdan Sorbye, Staffan Welin, Birgitte Federspiel, Henning Grønbæk, Per Hellman, Morten Ladekarl, Seppo W Langer, Jann Mortensen, Camilla Schalin-Jäntti, Anders Sundin, Anna Sundlöv, Espen Thiis-Evensen, Ulrich Knigge.   

Abstract

BACKGROUND: The diagnostic work-up and treatment of patients with neuroendocrine neoplasms (NENs) has undergone major recent advances and new methods are currently introduced into the clinic. An update of the WHO classification has resulted in a new nomenclature dividing NENs into neuroendocrine tumours (NETs) including G1 (Ki67 index ≤ 2%) and G2 (Ki67 index 3-20%) tumours and neuroendocrine carcinomas (NECs) with Ki67 index > 20%, G3. Aim. These Nordic guidelines summarise the Nordic Neuroendocrine Tumour Group's current view on how to diagnose and treat NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25140861     DOI： 10.3109/0284186X.2014.941999

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


  47 in total

Review 1.  Role of surgery in pancreatic neuroendocrine tumor.

Authors:  Kai Pun Wong; Julian Shun Tsang; Brian Hung-Hin Lang
Journal:  Gland Surg       Date:  2018-02

2.  Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Authors:  Stephan Petersenn; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: A case report.

Authors:  Guangjian Yang; Dan Li; Fangchao Zheng; Lin Yang
Journal:  Mol Clin Oncol       Date:  2018-03-26

Review 4.  Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Authors:  Sven-Petter Haugvik; Daniel Kaemmerer; Sebastien Gaujoux; Knut Jørgen Labori; Caroline Sophie Verbeke; Ivar Prydz Gladhaug
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

5.  Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.

Authors:  David R Martin; Elisa LaBauve; Joseph M Pomo; Vi K Chiu; Joshua A Hanson; Rama R Gullapalli
Journal:  Pancreas       Date:  2018-04       Impact factor: 3.327

6.  Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.

Authors:  Gunjan S Desai; Prasad Pande; Verushka Chhabra; Rajiv C Shah; Palepu Jagannath
Journal:  Indian J Gastroenterol       Date:  2019-12-04

7.  Biology and evolution of poorly differentiated neuroendocrine tumors.

Authors:  David S Rickman; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

8.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

9.  Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.

Authors:  Yugang Cheng; Hanxiang Zhan; Lei Wang; Jianwei Xu; Guangyong Zhang; Zongli Zhang; Sanyuan Hu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

10.  (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

Authors:  Ingrid H Olsen; Seppo W Langer; Birgitte H Federspiel; Jytte Oxbøl; Annika Loft; Anne Kiil Berthelsen; Jann Mortensen; Peter Oturai; Ulrich Knigge; Andreas Kjær
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.